Global Breast Cancer Drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2028
Request Covid 19 Impact
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
“Global Breast Cancer Drugs Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028” is a recent report generated by MarketResearch.biz. The global breast cancer drugs market report has been segmented on the basis of product type, technology and region.
Global Breast Cancer Drugs Market: Overview
Breast cancer is a type of cancer, that can occur more in women than in men. Some of the symptoms of the disease include bloody secretion from the nipple, a lump or block in the breast, and differences in the texture or shape of the nipple or breast. The treatment of breast cancer is depending on the stage of cancer. In addition, its treatment can consist of radiation, hormone therapy, chemotherapy, and surgery. Early detection of breast cancer is key to effective treatment of the disease. Also, early exposure of disease can lead to better outcomes including a number of treatment options, improved survival rate, and changed quality of life. There exist a rising pressure and demand for novel therapies or treatment owing to the rapidly growing prevalence of diseases. The strong pipeline is projected to provide effective and new treatment options and upgraded outcomes than already existing therapies.
Global Breast Cancer Drugs Market: Dynamics
The growing prevalence of the disease coupled with emerging and better novel therapies are some factors likely to fuel the global market growth. Global breast cancer drugs market is estimated to grow lucratively attributable to many major players are focusing on Research & Development of new and innovative treatments. They involve extensive research in order to develop novel drugs for the treatment of this disease to gain a higher market share. Various target and specific therapies have been designed and customized along with various advancements in drug delivery systems.
However, aging is taken as one of the extreme risk factors for breast cancer. In addition, according to Cancer Treatment Centers of America, most women of age above 60 years are more likely to be diagnosed with cancer, whereas only around 10% to 15% of cancer cases occur in women of age 45 or less than 45 years. High prevalence of this disease along with patent expiry are some other factors that are influencing government and private investment in research and development activities of new products.
Global Breast Cancer Drugs Market: Segment Analysis
The HER2 inhibitors segment is expected as the most lucrative segment of the global market. The rising incidence of HER2 positive breast cancer is the major reason behind the growth of this segment. Furthermore, the CDK 4/6 inhibitor segment is projected to grow at the fastest rate of growth during the forecast period. The aforesaid drugs are anticipated to increase the survival rate of patients suffered from metastatic breast cancer. Additionally, advancement and innovation of novel drugs, such as Verzenio launched by Eli Lilly and Company and Kisqali launched by Novartis AG and is estimated to drive growth of this segment in the upcoming years.
Global Breast Cancer Drugs Market: Regional Analysis
Rising awareness and high presence of established players coupled with R&D infrastructure are some factors that are contributing to the high growth of the North America Market. On the other hand, the Asia Pacific market is anticipated to witness the fastest CAGR over the forecast years. The rapid growth in the global demand for oncology drugs has prompted major drug providers and manufacturers to set up their manufacturing and R&D facilities in this region. Additionally, initiatives taken by numerous organizations in order to create people more aware and raise funds for the treatment of disease is projected to feed the regional market growth.
Global Breast Cancer Drugs Market Segmentation:
Segmentation by Drug Type:
- HER2 inhibitor
- Mitotic inhibitor
- Aromatase inhibitor
- CDK 4/6 inhibitor
- Hormonal receptor
Segmentation by Region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Hoffmann-La Roche Ltd.
- AbbVie, Inc.
- Celgene Corporation
- Merck & Co., Inc.
- Genzyme Corporation
- Janssen Global services LLC
- MacroGenics, Inc.
- Novartis AG
Request for TOC
Don't just take our word. We are trusted by these great companies!